PATH vs REGN
Uipath Inc (PATH) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the PATH and REGN stock pages for the full models.
Not investment advice.